- Will the industry consolidate, decentralize, or undergo a bimodal transformation? - How will the current trends affect the major market segments? - Which companies will enter the market and which will not survive? This new report from Venture Planning Group provides technological know-how of leading life science intermediates companies.
The report presents:
-Internally developed and acquired technologies, and related capabilities. -Proprietary technologies and patent litigations.
The companies analyzed in the report: BASF, Bayer/Lanxess, Cambrex, Clariant, DowPharma, DSM, Evonik, Lonza, Novasep, and Rhodia. Contains 35 pages
Table Of Contents
Life Science Intermediates Market Consolidation: Who will not survive? 1. BASF 2. Cambrex 3. Clariant 4. DowPharma 5. DSM 6. Evonik 7. Lanxess 8. Lonza 9. Novasep 10. Rhodia
For each company, the report presents:
- Internally developed and acquired technologies, and related capabilities.
- Proprietary technologies and patent litigations.